NEW YORK (GenomeWeb News) — Beckman Coulter has matched Inverness Medical Innovations’ offer to acquire Biosite, Biosite and Beckman said today.
 
As a result, Beckman and Biosite have signed a new agreement under which Beckman would buy Biosite for $90 a share, a per-share increase of $5 over the firm’s original bid.
 
The deal would now be worth an estimated $1.67 billion.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.